2.745
price up icon7.77%   0.235
 
loading
Immunitybio Inc stock is traded at $2.745, with a volume of 4.49M. It is up +7.77% in the last 24 hours and down -0.18% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.51
Open:
$2.54
24h Volume:
4.49M
Relative Volume:
0.70
Market Cap:
$2.45B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.8299
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-2.70%
1M Performance:
-0.18%
6M Performance:
-22.49%
1Y Performance:
-45.24%
1-Day Range:
Value
$2.54
$2.74
1-Week Range:
Value
$2.39
$2.75
52-Week Range:
Value
$2.28
$10.53

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
680
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.725 2.45B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.15 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.23 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.94 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.89 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.05 26.16B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Apr 21, 2025

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace

Apr 21, 2025
pulisher
Apr 17, 2025

Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Yahoo Finance

Apr 17, 2025
pulisher
Apr 16, 2025

Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey

Apr 16, 2025
pulisher
Apr 15, 2025

ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio Completes FDA License Application Submissions - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Is ImmunityBio Stock Heading Upwards? - timothysykes.com

Apr 14, 2025
pulisher
Apr 09, 2025

ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot

Apr 09, 2025
pulisher
Apr 09, 2025

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025
pulisher
Apr 09, 2025

Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - Insider Monkey

Apr 09, 2025
pulisher
Apr 08, 2025

ImmunityBio secures $75 million in direct offering - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio secures $75 million in direct offering By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio Stock: What’s Driving the Market? - timothysykes.com

Apr 08, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio Launches $75 Million Registered Direct Offering - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio (IBRX) Secures $75 Million in Direct Offering - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio raises $75 million in equity financing - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio Secures $75 Million in Direct Offering - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire

Apr 08, 2025
pulisher
Apr 07, 2025

IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 07, 2025

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - BioSpace

Apr 07, 2025
pulisher
Apr 04, 2025

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors - TradingView

Apr 04, 2025
pulisher
Apr 03, 2025

ImmunityBio: Taking Care Of Business (NASDAQ:IBRX) - Seeking Alpha

Apr 03, 2025
pulisher
Apr 01, 2025

ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC - PPF Group

Apr 01, 2025
pulisher
Mar 29, 2025

Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Is ImmunityBio, Inc. Stock a Buy Right Now? - timothysykes.com

Mar 28, 2025
pulisher
Mar 27, 2025

ImmunityBio’s Recent Surge: What’s Behind It? - timothysykes.com

Mar 27, 2025
pulisher
Mar 26, 2025

ImmunityBio to Host Investor Day - BioSpace

Mar 26, 2025
pulisher
Mar 25, 2025

Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey

Mar 25, 2025
pulisher
Mar 24, 2025

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates - EIN News

Mar 24, 2025
pulisher
Mar 19, 2025

ImmunityBio appoints Deloitte as new auditor By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

ImmunityBio appoints Deloitte as new auditor - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd - Law360

Mar 18, 2025
pulisher
Mar 18, 2025

ImmunityBio $10.5 Million Settlement Over Record Selloff Gets OK - Bloomberg Law News

Mar 18, 2025
pulisher
Mar 18, 2025

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company

Mar 18, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
SOON-SHIONG PATRICK
See remarks
Feb 22 '25
Option Exercise
0.00
114,329
0
29,588,261
Sachs David C.
Chief Financial Officer
Feb 22 '25
Option Exercise
0.00
40,650
0
241,480
Adcock Richard
CEO & President
Feb 22 '25
Option Exercise
0.00
152,439
0
412,585
Simon Barry J.
Director
Feb 22 '25
Option Exercise
0.00
15,243
0
3,249,024
Simon Barry J.
Director
Jan 22 '25
Option Exercise
2.00
110,020
219,864
3,233,781
Adcock Richard
CEO & President
Dec 31 '24
Option Exercise
0.00
34,483
0
277,621
Sachs David C.
Chief Financial Officer
Dec 31 '24
Option Exercise
0.00
30,397
0
216,235
LAUER REGAN J
Chief Accounting Officer
Dec 15 '24
Option Exercise
0.00
21,031
0
115,365
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):